Monitoring of Antiplatelet Therapy.

Publisher: Humana Press Country of Publication: United States NLM ID: 9214969 Publication Model: Print Cited Medium: Internet ISSN: 1940-6029 (Electronic) Linking ISSN: 10643745 NLM ISO Abbreviation: Methods Mol Biol Subsets: MEDLINE

Publication: Totowa, NJ : Humana Press
Original Publication: Clifton, N.J. : Humana Press,

Platelet Aggregation Inhibitors*/therapeutic use ; Platelet Aggregation Inhibitors*/pharmacology ; Ticlopidine*/pharmacology ; Ticlopidine*/therapeutic use; Humans ; Clopidogrel/therapeutic use ; Blood Platelets ; Platelet Function Tests/methods

In the late 1990s, the antithrombotic antiplatelet agent, clopidogrel, a P2Y12 inhibitor, was introduced. Around the same time, there was an increase in a number of new methods to measure platelet function (e.g., PFA-100 in 1995), and this has continued. It became evident that not all patients responded to clopidogrel in the same way and that some patients had a relative "resistance" to therapy, termed "high on-treatment platelet reactivity." This then led to some publications to advocate platelet function testing being used for patients on antiplatelet therapy. Platelet function testing was also suggested for use in patients awaiting cardiac surgery after stopping their antiplatelet therapy as a way of balancing thrombotic risk pre-surgery and bleeding risk perioperatively. This chapter will discuss some of the commonly used platelet function tests used in these settings, particularly those that are sometimes referred to as point-of-care tests or that require minimal laboratory sample manipulation. The latest guidance and recommendations for platelet function testing will be discussed following several clinical trials looking at the usefulness of platelet function testing in these clinical settings.
(© 2023. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.)

Orban M, Sibbing D (2013) Platelet function testing in patients with acute coronary syndrome. J Cardiovasc Transl Res. 6:371–377. (PMID: 2339728010.1007/s12265-013-9450-7)
Lordkipanidzé M, So D, Tanguay JF (2016) Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomark Med 10:903–918. (PMID: 2741497610.2217/bmm-2016-0070)
Kong R, Trimmings A, Hutchinson N, Gill R, Agarwal S, Davidson S, Arcari M (2015) Consensus recommendations for using the Multiplate for platelet function monitoring before cardiac surgery. Int J Lab Hematol 37:143–147. (PMID: 2505598310.1111/ijlh.12279)
Geisler T, Booth J, Tavlaki E et al (2015) High platelet reactivity in patients with acute coronary syndromes undergoing percutaneous coronary intervention: randomised controlled trial comparing prasugrel and clopidogrel. PLoS One 10:e0135037. (PMID: 26317618455262710.1371/journal.pone.0135037)
Price MJ, Endemann S, Gollapudi RR et al (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J. 29:992–1000. (PMID: 1826393110.1093/eurheartj/ehn046)
Sibbing D, Aradi D, Jacobshagen C, et al; TROPICAL-ACS Investigators (2017) Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet 390:1747–1757. (PMID: 2885507810.1016/S0140-6736(17)32155-4)
Collet JP, Thiele H, Barbato E, et al; ESC Scientific Document Group (2020) ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 42:1289–1367. (PMID: 10.1093/eurheartj/ehaa575)
Feng KY, Mahaffey KW (2020) Cangrelor in clinical use. Future Cardiol 16:89–102. (PMID: 3206747910.2217/fca-2019-0095)
Tantry US, Bliden KP, Chaudhary R, Novakovic M, Rout A, Gurbel PA (2020) Vorapaxar in the treatment of cardiovascular diseases. Future Cardiol 16:373–384. (PMID: 32308016817349710.2217/fca-2019-0090)
Mahtta D, Bavry A (2019) αIIbβ3 (GPIIb-IIIa) Antagonists. In: Michelson A (ed) Platelets, 4th edn. Elsevier Inc.
Patrono C, Rocca B (2012) Aspirin and other COX-1 inhibitors. In: Gresele P, Born GVR, Patrono C, Page CP (eds) Handbook of experimental pharmacology vol 210. Antiplatelet agents, 1st edn. Springer.
Cattaneo M (2019) P2Y12 Antagonists. In: Michelson A (ed) Platelets, 4th edn. Elsevier Inc.
Cattaneo M (2010) New P2Y12 Inhibitors. Circulation. 121:171–179. (PMID: 2004823410.1161/CIRCULATIONAHA.109.853069)
Storey RF, Kotha J, Smyth SS et al (2014) Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost. 111(5):883–891. (PMID: 2440255910.1160/TH13-07-0624)
Born GVR (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929. (PMID: 1387137510.1038/194927b0)
Cattaneo M, Cerletti C, Harrison P et al (2013) Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost. 11:1183–1189. (PMID: 10.1111/jth.12231)
Hayward CP, Moffat KA, Pai M, Liu Y, Seecharan J, McKay H, Webert KE, Cook RJ, Heddle NM (2008) An evaluation of methods for determining reference intervals for light transmission platelet aggregation tests on samples with normal or reduced platelet counts. Thromb Haemost. 100:134–145. (PMID: 18612548)
North American Specialized Coagulation Laboratory Association, NASCOLA Platelet Aggregation EQA System. https://nascola.com/PlateletEQA . Last accessed 18 Sept 2022.
Michelson AD, Cattaneo M, Eikelboom JW et al (2005) Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 3:1309–1311. (PMID: 1589285810.1111/j.1538-7836.2005.01351.x)
Cattaneo M (2004) Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 24:1980–1987. (PMID: 1538852610.1161/01.ATV.0000145980.39477.a9)
Gasparyan AY, Watson T, Lip GY (2008) The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 51:1829–1843. (PMID: 1846679710.1016/j.jacc.2007.11.080)
Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schrör K (2002) Towards a definition of aspirin resistance: a typological approach. Platelets. 13:37–40. (PMID: 1191883510.1080/09537100120104890)
Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG (2007) A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 28:1702–1708. (PMID: 1756967810.1093/eurheartj/ehm226)
Van Oosterom N, Barras M, Cottrell N, Bird R (2022) Platelet function assays for the diagnosis of aspirin resistance. Platelets. 33:329–338. (PMID: 3416617110.1080/09537104.2021.1942816)
Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4:1271–1278. (PMID: 1670697110.1111/j.1538-7836.2006.01958.x)
Cattaneo M (2011) The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 117:2102–2112. (PMID: 2096616710.1182/blood-2010-08-263111)
Savion N, Varon D (2006) Impact--the cone and plate(let) analyzer: testing platelet function and anti-platelet drug response. Pathophysiol Haemost Thromb. 35:83–88. (PMID: 1685535110.1159/000093548)
Spectre G, Brill A, Gural A, Shenkman B, Touretsky N, Mosseri E, Savion N, Varon D (2005) A new point-of-care method for monitoring anti-platelet therapy: application of the cone and plate(let) analyzer. Platelets. 16:293–299. (PMID: 1601198010.1080/09537100400028800)
van Werkum JW, Bouman HJ, Breet NJ, ten Berg JM, Hackeng CM (2010) The Cone-and-Plate(let) analyzer is not suitable to monitor clopidogrel therapy: a comparison with the flow cytometric VASP assay and optical aggregometry. Thromb Res. 126:44–49. (PMID: 2045265510.1016/j.thromres.2010.03.008)
Harrison P (2012) Advances in the monitoring of anti-P2Y12 therapy. Platelets. 23:510–525. (PMID: 2291672410.3109/09537104.2012.704650)
Cardinal DC, Flower RJ (1980) The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 3:135–358. (PMID: 739265410.1016/0160-5402(80)90024-8)
Würtz M, Hvas AM, Christensen KH, Rubak P, Kristensen SD, Grove EL (2014) Rapid evaluation of platelet function using the Multiplate® Analyzer. Platelets. 25:628–633. (PMID: 2424624110.3109/09537104.2013.849804)
Meen O, Brosstad F, Liestøl K, Kunszt G, Bendz B, Wettergreen M, Schjelderup NM, Andreassen T, Erikssen G (2012) Sequential ADP-stimulated light transmission and multiple electrode aggregometry in patients taking aspirin and clopidogrel after non ST-elevation myocardial infarction. Scand J Clin Lab Invest. 72:318–325. (PMID: 2272462610.3109/00365513.2012.666565)
Krüger JC, Meves SH, Kara K, Mügge A, Neubauer H (2014) Monitoring ASA and P2Y12-specific platelet inhibition--comparison of conventional (single) and multiple electrode aggregometry. Scand J Clin Lab Invest. 74:568–574. (PMID: 2529694510.3109/00365513.2014.913305)
Baryshnikova E, Di Dedda U, Ranucci M (2022) A comparative study of multiple electrode aggregometry technologies in cardiac surgery: different values, same clinical relevance. J Cardiothorac Vasc Anesth. 36:1927–1933. (PMID: 3494952210.1053/j.jvca.2021.11.030)
Kong R, Trimmings A, Hutchinson N, Gill R, Agarwal S, Davidson S, Arcari M (2015) Consensus recommendations for using the Multiplate(®) for platelet function monitoring before cardiac surgery. Int J Lab Hematol. 37:143–147. (PMID: 2505598310.1111/ijlh.12279)
Schimmer C, Hamouda K, Sommer SP, Özkur M, Hain J, Leyh R (2013) The predictive value of multiple electrode platelet aggregometry (multiplate) in adult cardiac surgery. Thorac Cardiovasc Surg. 61:733–743. (PMID: 2342033310.1055/s-0033-1333659)
Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mehilli J, Schomig A, von Beckerath N, Kastrati A (2010) Antiplatelet effects of clopidogrel and bleeding in patients under- going coronary stent placement. J Thromb Haemost 8:250–256. (PMID: 1994388210.1111/j.1538-7836.2009.03709.x)
Siller-Matula JM, Hintermeier A, Kastner J, Kreiner G, Maurer G, Kratochwil C, Lang IM, Delle-Karth G (2016) Distribution of clinical events across platelet aggregation values in all-comers treated with prasugrel and ticagrelor. Vascul Pharmacol. 79:6–10. (PMID: 2680476610.1016/j.vph.2016.01.003)
Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS (1999) Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation. 99:620–625. (PMID: 995065810.1161/01.CIR.99.5.620)
Lordkipanidzé M, Hvas AM, Harrison P. Clinical tests of platelet function. In: Michelson A (ed) Platelets, 4th edn. Elsevier Inc.
Liu Z, Tian R, Wang Y, Chen Q, Li J, Xu L, Zhang S (2020) Platelet inhibition with ticagrelor versus clopidogrel in diabetic patients after percutaneous coronary intervention for chronic coronary syndromes. Thromb Haemost. 120:1221–1229. (PMID: 3266848310.1055/s-0040-1713375)
Paniccia R, Antonucci E, Maggini N et al (2010) Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb Haemost. 104:287–292. (PMID: 20458439)
Harrison P (2005) The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br J Haematol. 130:3–10. (PMID: 1598233910.1111/j.1365-2141.2005.05511.x)
Edwards A, Jakubowski JA, Rechner AR, Sugidachi A, Harrison P (2012) Evaluation of the INNOVANCE PFA P2Y test cartridge: sensitivity to P2Y(12) blockade and influence of anticoagulant. Platelets. 23:106–115. (PMID: 2184836810.3109/09537104.2011.601361)
Tsantes A, Ikonomidis I, Papadakis I et al (2012) Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance. Platelets. 23:481–489. (PMID: 2264649210.3109/09537104.2012.689037)
Campbell J, Ridgway H, Carville D (2008) Plateletworks: a novel point of care platelet function screen. Mol Diagn Ther. 12:253–258. (PMID: 1865252110.1007/BF03256290)
Breet NJ, van Werkum JW, Bouman HJ et al (2010) Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 303:754–762. (PMID: 2017928510.1001/jama.2010.181)
Luddington RJ (2005) Thromboelastography/thromboelastometry. Clin Lab Haematol 27:81–90. (PMID: 1578412210.1111/j.1365-2257.2005.00681.x)
Agarwal S, Coakley M, Reddy K, Riddell A, Mallett S (2006) Quantifying the effect of antiplatelet therapy: a comparison of the platelet function analyzer (PFA-100) and modified thromboelastography (mTEG) with light transmission platelet aggregometry. Anesthesiology. 105:676–683. (PMID: 1700606410.1097/00000542-200610000-00011)
Preisman S, Kogan A, Itzkovsky K, Leikin G, Raanani E (2010) Modified thromboelastography evaluation of platelet dysfunction in patients undergoing coronary artery surgery. Eur J Cardiothorac Surg. 37:1367–1374. (PMID: 2018149010.1016/j.ejcts.2009.12.044)
Collyer TC, Gray DJ, Sandhu R, Berridge J, Lyons G (2009) Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by Thromboelastography Platelet Mapping. Br J Anaesth. 102:492–498. (PMID: 1928676710.1093/bja/aep039)
Olechowski B, Dalton RT, Khanna V, Ashby A, Vavyla M, Mariathas M, Harris S, Nicholas Z, Mahmoudi M, Curzen N (2018) Detection of individual responses to clopidogrel: validation of a novel, rapid analysis using thromboelastography 6s. Cardiovasc Ther. 36:e12433. (PMID: 2968291110.1111/1755-5922.12433)
Kirmani BH, Johnson RI, Agarwal S (2017) Platelet function testing in cardiac surgery: a comparative study of electrical impedance aggregometry and thromboelastography. Platelets. 28:550–554. (PMID: 2827706210.1080/09537104.2016.1237626)
Schultz-Lebahn A, Nissen PH, Pedersen TF, Tang M, Hvas AM (2022) Platelet function assessed by ROTEM® platelet in patients receiving antiplatelet therapy during cardiac and vascular surgery. Scand J Clin Lab Invest. 82(1):18–27. (PMID: 3489029310.1080/00365513.2021.2012820)
Polzin A, Helten C, Dannenberg L et al (2019) Platelet reactivity in patients on aspirin and clopidogrel therapy measured by a new bedside whole-blood assay. J Cardiovasc Pharmacol. 73:40–47. (PMID: 3038360610.1097/FJC.0000000000000631)
Hulshof AM, Olie RH, Vries MJA, Verhezen PWM, van der Meijden PEJ, Ten Cate H, Henskens YMC (2021) Rotational thromboelastometry in high-risk patients on dual antithrombotic therapy after percutaneous coronary intervention. Front Cardiovasc Med. 8:788137. (PMID: 35004899872735910.3389/fcvm.2021.788137)
Baryshnikova E, Di Dedda U, Ranucci MA (2019) Comparative study of SEER sonorheometry versus standard coagulation tests, rotational thromboelastometry, and multiple electrode aggregometry in cardiac surgery. J Cardiothorac Vasc Anesth. 33:1590–1598. (PMID: 3073712210.1053/j.jvca.2019.01.011)
Gurbel PA, Tantry US, Bliden KP, Fisher R, Sukavaneshvar S, Dahlen J, Speros PC (2021) Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y 12 antagonists. J Thromb Thrombolysis. 52:272–280. (PMID: 3414338410.1007/s11239-021-02498-0)
Kaikita K, Hosokawa K, Dahlen JR, Tsujita K (2019) Total Thrombus-Formation Analysis System (T-TAS): clinical application of quantitative analysis of thrombus formation in cardiovascular disease. Thromb Haemost. 119:1554–1562. (PMID: 3133055810.1055/s-0039-1693411)
Zheng KL, Wallen H, Aradi D, Godschalk TC, Hackeng CM, Dahlen JR, Ten Berg JM (2022) The Total Thrombus Formation (T-TAS) platelet (PL) assay, a novel test that evaluates whole blood platelet thrombus formation under physiological conditions. Platelets 33:273–277. (PMID: 3355469510.1080/09537104.2021.1882669)
Hosokawa K, Ohnishi T, Sameshima H, Miura N, Ito T, Koide T, Maruyama I (2013) Analysing responses to aspirin and clopidogrel by measuring platelet thrombus formation under arterial flow conditions. Thromb Haemost. 109:102–111. (PMID: 2317905510.1160/TH12-06-0441)
Arima Y, Kaikita K, Ishii M et al (2016) Assessment of platelet-derived thrombogenicity with the total thrombus-formation analysis system in coronary artery disease patients receiving antiplatelet therapy. J Thromb Haemost. 14:850–859. (PMID: 2677329810.1111/jth.13256)
Yamazaki M, Ohnishi T, Hosokawa K et al (2016) Measurement of residual platelet thrombogenicity under arterial shear conditions in cerebrovascular disease patients receiving antiplatelet therapy. J Thromb Haemost. 14:1788–1797. (PMID: 2732845710.1111/jth.13391)
Gibbs NM (2009) Point-of-care assessment of antiplatelet agents in the perioperative period: a review. Anaesth Intensive Care. 37:354–369. (PMID: 1949985510.1177/0310057X0903700317)
Tucci MA, Ganter MT, Hamiel CR, Klaghofer R, Zollinger A, Hofer CK (2006) Platelet function monitoring with the Sonoclot analyzer after in vitro tirofiban and heparin administration. J Thorac Cardiovasc Surg 131:1314–1322. (PMID: 1673316410.1016/j.jtcvs.2006.01.041)
Tanaka KA, Katori N, Szlam F, Sato N, Kelly AB, Levy JH (2004) Effects of tirofiban on haemostatic activation in vitro. Br J Anaesth. 93:263–269. (PMID: 1519462610.1093/bja/aeh193)
Viola F, Lin-Schmidt X, Bhamidipati C, Haverstick DM, Walker WF, Ailawadi G, Lawrence MB (2016) Sonorheometry assessment of platelet function in cardiopulmonary bypass patients: correlation of blood clot stiffness with platelet integrin αIIbβ3 activity, aspirin usage, and transfusion risk. Thromb Res. 138:96–102. (PMID: 2668832410.1016/j.thromres.2015.11.036)
Valgimigli M, Bueno H, Byrne RA, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies (2017) ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 39:213–260. (PMID: 10.1093/eurheartj/ehx419)
Neumann FJ, Sousa-Uva M, Ahlsson A, et al; ESC Scientific Document Group (2019) ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 40(2):87–165. (PMID: 3016543710.1093/eurheartj/ehy394)
Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (2018) ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 72:2915–2931. (PMID: 3052265410.1016/j.jacc.2018.09.057)
Dalby MC, Davidson SJ, Burman JF, Davies SW (2000) Diurnal variation in platelet aggregation with the PFA-100 platelet function analyser. Platelets. 11:320–324. (PMID: 1108345610.1080/09537100050144731)
Cattaneo M (2012) The role of laboratory monitoring in antiplatelet therapy. In: Gresele P, Born GVR, Patrono C, Page CP (eds) Handbook of experimental pharmacology vol 210. Antiplatelet agents, 1st edn. Springer.
Bernlochner I, Steinhubl S, Braun S et al (2010) Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost. 104:1193–1200. (PMID: 2083874410.1160/TH10-05-0266)
Bongiovanni D, Han J, Klug M et al (2022) Role of reticulated platelets in cardiovascular disease. Arterioscler Thromb Vasc Biol. 42:527–539. (PMID: 3532156210.1161/ATVBAHA.121.316244)
Chau KH, Kirtane AJ, Easterwood RM et al (2021) Stent thrombosis risk over time on the basis of clinical presentation and platelet reactivity: analysis from ADAPT-DES. JACC Cardiovasc Interv. 14:417–427. (PMID: 3351669010.1016/j.jcin.2020.12.005)
Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ (2012) A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 59:2159–2164. (PMID: 2252025010.1016/j.jacc.2012.02.026)
Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ (2011) Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 124:1132–1137. (PMID: 2187591310.1161/CIRCULATIONAHA.111.029165)
Collet JP, Cuisset T, Rangé G, et al; ARCTIC Investigators (2012) Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 367:2100–2109. (PMID: 2312143910.1056/NEJMoa1209979)
Cayla G, Cuisset T, Silvain J, et al; ANTARCTIC investigators. (2016) Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open-label, blinded-endpoint, randomised controlled superiority trial. Lancet. 388:2015-2022.
Mansouritorghabeh H, de Laat B, Roest M (2020) Current methods of measuring platelet activity: pros and cons. Blood Coagul Fibrinolysis. 31:426–433. (PMID: 3283380110.1097/MBC.0000000000000941)
Lordkipanidzé M, So D, Tanguay JF (2016) Platelet function testing as a biomarker for efficacy of antiplatelet drugs. Biomark Med. 10:903–918. (PMID: 2741497610.2217/bmm-2016-0070)

Keywords: AggreGuide A-100; Antiplatelet; Multiplate; PFA-100/PFA-200; Plateletworks; Quantra; ROTEM; Sonoclot; T-TAS; TEG; VerifyNow

0 (Platelet Aggregation Inhibitors)
A74586SNO7 (Clopidogrel)
OM90ZUW7M1 (Ticlopidine)

Date Created: 20230519 Date Completed: 20230522 Latest Revision: 20230523

20240829

10.1007/978-1-0716-3175-1_25

37204725